Developer docs
API playgroundTry for free, no card

Search company profiles

Exagen

Full company profile

uuid0002b79

Namestring
Exagen
Legal namestring
Exagen Inc.
Websiteurl
exagen.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Exagen Inc. (NASDAQ: XGN) is a publicly traded commercial-stage life sciences company that develops and commercializes proprietary diagnostic tests for autoimmune rheumatic diseases, primarily serving rheumatologists, biopharmaceutical companies, and academic medical centers. The company's core offering is the AVISE testing portfolio, anchored by AVISE CTD and AVISE Lupus, which leverage its proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology—a platform that measures hydrolyzed complement activation byproducts (EC4d, BC4d, TC4d) bound to circulating erythrocytes, platelets, and lymphocytes. Cell binding confers marker stability for the life of the cells, providing differentiated diagnostic accuracy (AUC of 0.90, specificity above 98%) and the ability to identify approximately 25% more SLE patients missed by conventional serologic tests alone.

Exagen generates revenue primarily on a per-test basis through healthcare provider orders fulfilled at its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The Q1 2026 average selling price was $444 per test (+6% YoY), with full-year 2025 revenue of $66.6 million (20% YoY growth) and 2026 guidance of $70-73 million. Distribution is sales-led through a rheumatology-focused sales team targeting over 7,500 ordering providers, supplemented by biopharma partnerships (AbbVie, GSK, Janssen, Horizon Therapeutics, Immunovant, UCB) for clinical trial support and commercialization collaborations. The product line spans the continuum of autoimmune care—diagnosis (AVISE Lupus, AVISE CTD), disease activity monitoring (AVISE SLE Monitor), prognosis (AVISE SLE Prognostic), therapeutic drug monitoring (AVISE MTX, AVISE HCQ), and adjacent indications (AVISE APS, AVISE Vasculitis AAV, AVISE Anti-CarP), with recent expansions into anti-PAD4 and seronegative RA markers.

The company has accumulated a substantial clinical data asset exceeding 1.5 million analyzed data points across over 800,000 unique patients and 20+ years of operation, with over 1 million patients tested since the 2012 AVISE Lupus launch. Clinical validation is supported by more than 300 peer-reviewed publications and a 2026 systematic review in Lupus Science & Medicine. The company deploys AI/ML through a DataRobot partnership for predictive modeling and pattern recognition across its biomarker data portfolio. Despite top-line growth, Exagen reported a 2025 net loss of approximately $20 million against $32.2 million in cash, prompting recent capital raises including a $25 million Perceptive Advisors-led round in April 2025 and an additional $20.2 million round in May 2025. Founded in 2011 and headquartered in Vista, California, Exagen is led by CEO John Aballi (since October 2022) and Executive Chair Tina Nova, PhD.

Short descriptiontext

Exagen Inc. (NASDAQ: XGN) is a commercial-stage diagnostics company that develops and commercializes the AVISE testing portfolio, proprietary autoimmune rheumatic disease tests based on Cell-Bound Complement Activation Products (CB-CAPs) technology, serving rheumatologists, biopharma partners, and academic medical centers through its CLIA-certified laboratory in Vista, California.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersVista, United States
HQ citystring
Vista
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autoimmune diagnostic testing, connective tissue disease diagnostics, lupus biomarker testing, clinical laboratory services, complement activation assays
Industry6 codes
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Autoimmune Diagnostic Testing
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AVISE Diagnostic Testing
TypeOne Time License
Description

Exagen generates revenue primarily from selling its AVISE diagnostic tests (AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, AVISE HCQ, AVISE Vasculitis AAV, AVISE Anti-CarP) to healthcare providers and rheumatologists. Revenue is generated per test, with Q1 2026 average selling price of $444 per test, a 6% increase year-over-year. The company reports record quarterly revenues ($17.3M Q1 2026) and full-year 2025 revenue of $66.6M, up 20% year-over-year.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Per-test laboratory diagnostic services
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Revenue generated per diagnostic test performed. Q1 2026 ASP: $444 per test (+6% YoY). 2025 ASP: $441 per test (+7% YoY). No public pricing available; tests ordered by healthcare providers.

stocktitan.net
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1AVISE
Description

Next-generation autoimmune testing product line including AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, AVISE HCQ, AVISE Vasculitis AAV, and AVISE Anti-CarP tests

exagen.com
+5 more records
Core offering1 text field

Exagen is a commercial-stage life sciences company that develops and performs proprietary AVISE diagnostic tests for autoimmune rheumatic diseases through its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The portfolio centers on AVISE CTD and AVISE Lupus, powered by the company's proprietary Cell-Bound Complement Activation Products (CB-CAPs) biomarker technology, and is supplemented by disease monitoring, prognostic, drug monitoring, vasculitis, and rheumatoid arthritis testing products sold primarily to rheumatologists, healthcare providers, and biopharma companies on a per-test basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • AVISE Lupus identified approximately 25% more systemic lupus erythematosus patients than conventional serologic tests alone
+4 more records
Product overview1 text field

Exagen is a commercial-stage life sciences company offering the AVISE diagnostic testing portfolio, a suite of products based on proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology. The core offering centers on AVISE CTD (connective tissue disease diagnostic) and AVISE Lupus (SLE diagnostic), supported by monitoring, prognostic, and drug monitoring add-on tests including AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, and AVISE HCQ. Additional products include AVISE Vasculitis AAV for ANCA-associated vasculitis and AVISE Anti-CarP for rheumatoid arthritis risk stratification. All tests are performed in Exagen's CAP-accredited, CLIA-certified laboratory in Vista, California.

Product and service11 records
1AVISE CTD
CategoryAutoimmune Diagnostic Testing
Description

Comprehensive diagnostic tool powered by CB-CAPs technology designed to help distinguish patients with connective tissue disease (CTD) or similar diseases with overlapping symptoms. Includes SLE and connective tissue disease testing with markers such as EC4d, BC4d, and TC4d. Used by rheumatologists for differential diagnosis.

2AVISE Lupus
CategoryAutoimmune Diagnostic Testing
Description

SLE (Systemic Lupus Erythematosus) diagnostic test that uses CB-CAPs biomarkers to uniquely identify approximately 25% of SLE patients who would be missed by conventional serologic tests alone, with AUC of 0.90 and specificity above 98%. Used by rheumatologists for SLE diagnosis.

3AVISE SLE Monitor
CategoryAutoimmune Diagnostic Testing
Description

Laboratory monitoring tool leveraging Erythrocyte-Bound C4d (EC4d) to help assess disease activity and monitor patients with SLE over time. Used by rheumatologists for ongoing SLE patient management.

4AVISE SLE Prognostic
CategoryAutoimmune Diagnostic Testing
Description

10-marker prognostic panel developed to assess patient risk for Thrombosis, Cardiovascular events, Lupus Nephritis, and Neuropsychiatric Lupus. Includes anti-C1q biomarker for renal activity assessment. Used by rheumatologists for risk stratification.

5AVISE APS
CategoryAutoimmune Diagnostic Testing
Description

Advanced antiphospholipid syndrome diagnostic test composed of biomarkers including anti-phosphatidylserine/prothrombin (PS/PT), anti-cardiolipin, and anti-β2-Glycoprotein 1 to assess patient risk for APS and thrombosis. Used by rheumatologists for APS diagnosis.

6AVISE MTX
CategoryTherapeutic Drug Monitoring
Description

Methotrexate Polyglutamate Measuring Test providing accurate measurement of active MTX metabolites (MTXPGs) to help physicians assess patient exposure to methotrexate therapy and inform dosing decisions. Used by rheumatologists for therapeutic drug monitoring.

7AVISE HCQ
CategoryTherapeutic Drug Monitoring
Description

Hydroxychloroquine blood level test measuring drug levels in whole blood to help physicians assess patient compliance, disease flare risk, and therapeutic decision making for SLE patients on HCQ therapy. Used by rheumatologists for therapeutic drug monitoring.

8AVISE Vasculitis AAV
CategoryAutoimmune Diagnostic Testing
Description

Complete panel of ANCA-associated markers for swift and accurate assessment of ANCA-associated vasculitis (AAV) disease state, including c-ANCA, p-ANCA, anti-PR3, anti-MPO, and anti-GBM assays. Used by rheumatologists for vasculitis diagnosis.

9AVISE Anti-CarP
CategoryAutoimmune Diagnostic Testing
Description

Blood test measuring anti-carbamylated protein antibodies to identify rheumatoid arthritis patients with increased risk for erosive joint damage, useful for patients negative for traditional biomarkers RF and ACPA. Used by rheumatologists for RA risk stratification.

10AVISE Anti-PAD4
CategoryAutoimmune Diagnostic Testing
Description

Anti-PAD4 antibody biomarker test launched in October 2025 supporting rheumatoid arthritis diagnostics. Used by rheumatologists for RA diagnosis.

11Biopharma and Clinical Trial Services
CategoryClinical Trial and Biopharma Services
Description

Customizable diagnostic testing services for biopharmaceutical companies developing autoimmune disease therapeutics. Includes biomarker discovery, clinical trial patient selection and monitoring, technology transfer, and post-FDA approval real-world evidence generation. Used by biopharma companies and CROs.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biopharma partner collaborating on autoimmune disease research and development. AbbVie is one of Exagen's key biopharma partners listed on their collaborations page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biopharma partner collaborating on autoimmune disease research and development. GSK is listed as a biopharma partner on Exagen's collaborations page.

3Horizon Therapeutics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biopharma partner collaborating on autoimmune disease research and development.

exagen.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biopharma partner collaborating on autoimmune disease research and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biopharma partner collaborating on autoimmune disease research and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biopharma partner collaborating on autoimmune disease research and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator in autoimmune disease research and diagnostic development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds26 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exagen

Autoimmune Diagnostic Testingexagen.com

Exagen Inc. (NASDAQ: XGN) is a commercial-stage diagnostics company that develops and commercializes the AVISE testing portfolio, proprietary autoimmune rheumatic disease tests based on Cell-Bound Complement Activation Products (CB-CAPs) technology, serving rheumatologists, biopharma partners, and academic medical centers through its CLIA-certified laboratory in Vista, California.

What Exagen does

Exagen Inc. (NASDAQ: XGN) is a publicly traded commercial-stage life sciences company that develops and commercializes proprietary diagnostic tests for autoimmune rheumatic diseases, primarily serving rheumatologists, biopharmaceutical companies, and academic medical centers. The company's core offering is the AVISE testing portfolio, anchored by AVISE CTD and AVISE Lupus, which leverage its proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology—a platform that measures hydrolyzed complement activation byproducts (EC4d, BC4d, TC4d) bound to circulating erythrocytes, platelets, and lymphocytes. Cell binding confers marker stability for the life of the cells, providing differentiated diagnostic accuracy (AUC of 0.90, specificity above 98%) and the ability to identify approximately 25% more SLE patients missed by conventional serologic tests alone.

Exagen generates revenue primarily on a per-test basis through healthcare provider orders fulfilled at its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The Q1 2026 average selling price was $444 per test (+6% YoY), with full-year 2025 revenue of $66.6 million (20% YoY growth) and 2026 guidance of $70-73 million. Distribution is sales-led through a rheumatology-focused sales team targeting over 7,500 ordering providers, supplemented by biopharma partnerships (AbbVie, GSK, Janssen, Horizon Therapeutics, Immunovant, UCB) for clinical trial support and commercialization collaborations. The product line spans the continuum of autoimmune care—diagnosis (AVISE Lupus, AVISE CTD), disease activity monitoring (AVISE SLE Monitor), prognosis (AVISE SLE Prognostic), therapeutic drug monitoring (AVISE MTX, AVISE HCQ), and adjacent indications (AVISE APS, AVISE Vasculitis AAV, AVISE Anti-CarP), with recent expansions into anti-PAD4 and seronegative RA markers.

The company has accumulated a substantial clinical data asset exceeding 1.5 million analyzed data points across over 800,000 unique patients and 20+ years of operation, with over 1 million patients tested since the 2012 AVISE Lupus launch. Clinical validation is supported by more than 300 peer-reviewed publications and a 2026 systematic review in Lupus Science & Medicine. The company deploys AI/ML through a DataRobot partnership for predictive modeling and pattern recognition across its biomarker data portfolio. Despite top-line growth, Exagen reported a 2025 net loss of approximately $20 million against $32.2 million in cash, prompting recent capital raises including a $25 million Perceptive Advisors-led round in April 2025 and an additional $20.2 million round in May 2025. Founded in 2011 and headquartered in Vista, California, Exagen is led by CEO John Aballi (since October 2022) and Executive Chair Tina Nova, PhD.

Exagen firmographics

Firmographics
Name
Exagen
Legal name
Exagen Inc.
Website
https://exagen.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Exagen Inc. (NASDAQ: XGN) is a commercial-stage diagnostics company that develops and commercializes the AVISE testing portfolio, proprietary autoimmune rheumatic disease tests based on Cell-Bound Complement Activation Products (CB-CAPs) technology, serving rheumatologists, biopharma partners, and academic medical centers through its CLIA-certified laboratory in Vista, California.
Ownership category
akta.pro rank

Exagen industry classification

Industry
Product category
Autoimmune Diagnostic Testing
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Autoimmune diagnostic testing
  • Connective tissue disease diagnostics
  • Lupus biomarker testing
  • Clinical laboratory services
  • Complement activation assays

Where Exagen is headquartered

Location

Headquarters

HQ city
Vista
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Exagen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. AVISE Diagnostic Testing: Exagen generates revenue primarily from selling its AVISE diagnostic tests (AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, AVISE HCQ, AVISE Vasculitis AAV, AVISE Anti-CarP) to healthcare providers and rheumatologists. Revenue is generated per test, with Q1 2026 average selling price of $444 per test, a 6% increase year-over-year. The company reports record quarterly revenues ($17.3M Q1 2026) and full-year 2025 revenue of $66.6M, up 20% year-over-year.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPer-test laboratory diagnostic services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Exagen product offering

Product offering

Core offering

Exagen is a commercial-stage life sciences company that develops and performs proprietary AVISE diagnostic tests for autoimmune rheumatic diseases through its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The portfolio centers on AVISE CTD and AVISE Lupus, powered by the company's proprietary Cell-Bound Complement Activation Products (CB-CAPs) biomarker technology, and is supplemented by disease monitoring, prognostic, drug monitoring, vasculitis, and rheumatoid arthritis testing products sold primarily to rheumatologists, healthcare providers, and biopharma companies on a per-test basis.

Product overview

Exagen is a commercial-stage life sciences company offering the AVISE diagnostic testing portfolio, a suite of products based on proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology. The core offering centers on AVISE CTD (connective tissue disease diagnostic) and AVISE Lupus (SLE diagnostic), supported by monitoring, prognostic, and drug monitoring add-on tests including AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, and AVISE HCQ. Additional products include AVISE Vasculitis AAV for ANCA-associated vasculitis and AVISE Anti-CarP for rheumatoid arthritis risk stratification. All tests are performed in Exagen's CAP-accredited, CLIA-certified laboratory in Vista, California.

Differentiator

Problem solved

Functional benefit

Brands

  • AVISE: Next-generation autoimmune testing product line including AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, AVISE HCQ, AVISE Vasculitis AAV, and AVISE Anti-CarP tests
  • AVISE CTD
  • AVISE Lupus
  • AVISE SLE Monitor
  • AVISE SLE Prognostic
  • CB-CAPs

Products and services

  • AVISE CTD Comprehensive diagnostic tool powered by CB-CAPs technology designed to help distinguish patients with connective tissue disease (CTD) or similar diseases with overlapping symptoms. Includes SLE and connective tissue disease testing with markers such as EC4d, BC4d, and TC4d. Used by rheumatologists for differential diagnosis.
  • AVISE Lupus SLE (Systemic Lupus Erythematosus) diagnostic test that uses CB-CAPs biomarkers to uniquely identify approximately 25% of SLE patients who would be missed by conventional serologic tests alone, with AUC of 0.90 and specificity above 98%. Used by rheumatologists for SLE diagnosis.
  • AVISE SLE Monitor Laboratory monitoring tool leveraging Erythrocyte-Bound C4d (EC4d) to help assess disease activity and monitor patients with SLE over time. Used by rheumatologists for ongoing SLE patient management.
  • AVISE SLE Prognostic 10-marker prognostic panel developed to assess patient risk for Thrombosis, Cardiovascular events, Lupus Nephritis, and Neuropsychiatric Lupus. Includes anti-C1q biomarker for renal activity assessment. Used by rheumatologists for risk stratification.
  • AVISE APS Advanced antiphospholipid syndrome diagnostic test composed of biomarkers including anti-phosphatidylserine/prothrombin (PS/PT), anti-cardiolipin, and anti-β2-Glycoprotein 1 to assess patient risk for APS and thrombosis. Used by rheumatologists for APS diagnosis.
  • AVISE MTX Methotrexate Polyglutamate Measuring Test providing accurate measurement of active MTX metabolites (MTXPGs) to help physicians assess patient exposure to methotrexate therapy and inform dosing decisions. Used by rheumatologists for therapeutic drug monitoring.
  • AVISE HCQ Hydroxychloroquine blood level test measuring drug levels in whole blood to help physicians assess patient compliance, disease flare risk, and therapeutic decision making for SLE patients on HCQ therapy. Used by rheumatologists for therapeutic drug monitoring.
  • AVISE Vasculitis AAV Complete panel of ANCA-associated markers for swift and accurate assessment of ANCA-associated vasculitis (AAV) disease state, including c-ANCA, p-ANCA, anti-PR3, anti-MPO, and anti-GBM assays. Used by rheumatologists for vasculitis diagnosis.
  • AVISE Anti-CarP Blood test measuring anti-carbamylated protein antibodies to identify rheumatoid arthritis patients with increased risk for erosive joint damage, useful for patients negative for traditional biomarkers RF and ACPA. Used by rheumatologists for RA risk stratification.
  • AVISE Anti-PAD4 Anti-PAD4 antibody biomarker test launched in October 2025 supporting rheumatoid arthritis diagnostics. Used by rheumatologists for RA diagnosis.
  • Biopharma and Clinical Trial Services Customizable diagnostic testing services for biopharmaceutical companies developing autoimmune disease therapeutics. Includes biomarker discovery, clinical trial patient selection and monitoring, technology transfer, and post-FDA approval real-world evidence generation. Used by biopharma companies and CROs.

Quantifiable outcome

  • AVISE Lupus identified approximately 25% more systemic lupus erythematosus patients than conventional serologic tests alone
  • +4 more outcomes

Companies that use Exagen

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Exagen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature9 records

Exagen partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core.

  • AbbViecoreStrategic or Co-development PartnerBiopharma partner collaborating on autoimmune disease research and development. AbbVie is one of Exagen's key biopharma partners listed on their collaborations page.
  • GSKcoreStrategic or Co-development PartnerBiopharma partner collaborating on autoimmune disease research and development. GSK is listed as a biopharma partner on Exagen's collaborations page.
  • Horizon TherapeuticscoreStrategic or Co-development PartnerBiopharma partner collaborating on autoimmune disease research and development.
  • ImmunovantcoreStrategic or Co-development PartnerBiopharma partner collaborating on autoimmune disease research and development.
  • JanssencoreStrategic or Co-development PartnerBiopharma partner collaborating on autoimmune disease research and development.
  • UCBcoreStrategic or Co-development PartnerBiopharma partner collaborating on autoimmune disease research and development.
  • Brigham and Women's HospitalcoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • Johns Hopkins MedicinecoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • Hospital for Special SurgerycoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • Duke UniversitycoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • NYU Langone HealthcoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • Northwestern University Feinberg School of MedicinecoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • Emory UniversitycoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • David Geffen School of Medicine at UCLAcoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • Montefiore Health SystemcoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • Northwell HealthcoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.
  • AdventHealthcoreStrategic or Co-development PartnerAcademic collaborator in autoimmune disease research and diagnostic development.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Exagen competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

Exagen social profiles

Digital presence

Exagen compliance and trust

Trust signal

Compliance3 records

Exagen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exagen leadership team

Management profile

Number of profiles

Profiles16 records

Exagen funding detail

Funding detail

Funding overview

Funding rounds26 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exagen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exagen

What does Exagen do?

Exagen is a commercial-stage life sciences company that develops and performs proprietary AVISE diagnostic tests for autoimmune rheumatic diseases through its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The portfolio centers on AVISE CTD and AVISE Lupus, powered by the company's proprietary Cell-Bound Complement Activation Products (CB-CAPs) biomarker technology, and is supplemented by disease monitoring, prognostic, drug monitoring, vasculitis, and rheumatoid arthritis testing products sold primarily to rheumatologists, healthcare providers, and biopharma companies on a per-test basis.

Is Exagen a public or private company?

Exagen is a public company. It is classified as public and is currently operating.

When was Exagen founded?

Exagen was founded in 2011. It employs 101 to 250 people.

Where is Exagen based?

Exagen is headquartered in Vista, United States, in the North America region.

How does Exagen make money?

One revenue line is on record: AVISE Diagnostic Testing.

Does Exagen have an API?

No public API is recorded for Exagen.

What industry is Exagen in?

Exagen's product category is Autoimmune Diagnostic Testing. Its primary akta.pro industry code is HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics, with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsExagen (NASDAQ:XGN) Stock Rating Cut to “Sell” at Wall Street ZenWall Street Zen downgraded Exagen from 'hold' to 'sell' in a research report. The company reported Q2 EPS of -$0.25, missing the -$0.18 consensus, and insiders sold shares. Analysts average a 'Moderate Buy' rating with a $9.88 price target.Simply Wall StExagen Inc. (NASDAQ:XGN) Third-Quarter Results: Here's What Analysts Are Forecasting For Next YearExagen's shares fell 42% after Q3 results, with revenue at $18m and statutory losses of $0.25 per share. Analysts forecast 2027 revenue of $80.8m, a 12% improvement, but losses to $0.56 per share, a 26% increase. The consensus price target remains at $10.29, with revenue growth expected slower than the industry.TradingViewCanaccord Genuity maintains Exagen at Buy, lowers price target to $9 from $11Canaccord Genuity maintained Exagen at Buy and lowered its price target to $9 from $11, an 18.2% decrease. The target implies an upside of 71.1% from the Nov 10 close of $5.26. Recent analyst price targets range from $9 to $11.TradingViewBTIG maintains Exagen at Buy, keeps price target at $9BTIG maintained Exagen at Buy and kept its price target at $9. The target implies a 71.1% upside from the Nov 10 close of $5.26. The rating is not investment advice.Seeking AlphaExagen reiterates $72M-$75M 2026 revenue outlook as myositis launch targets early 2027 (NASDAQ:XGN)Exagen reiterated its full-year 2026 revenue guidance of $72 million to $75 million, citing a record third quarter. The company also targets an early 2027 launch for its myositis product.Seeking AlphaExagen Inc. (XGN) Q3 2026 Earnings Call TranscriptExagen Inc. held its Q3 2026 earnings call on November 10, 2026, with CEO John Aballi and CFO Jeff Black. The call included forward-looking statements and non-GAAP measures, but no financial results were disclosed in the transcript.MarketWatchExagen Shares Plunge on 3Q Earnings MissExagen shares fell 33% to $4.75 after the company reported a Q3 loss of $6.3 million, wider than the expected $5.4 million. Revenue rose to $18.4 million, but the loss per share of 25 cents exceeded the 18-cent consensus. The company reiterated full-year revenue guidance of $72–75 million.Investing.comEarnings call transcript: Exagen’s Q3 2026 revenue edges past forecasts as shares fallExagen reported Q3 2026 revenue of $18.4 million, beating the $18.34 million estimate, with trailing 12-month ASP reaching a record $451 per test. The company reiterated full-year 2026 revenue guidance of $72 million to $75 million and said its myositis test is on track for an early 2027 launch.Quiver QuantitativeEXAGEN DIAGNOSTICS ($XGN) Releases Q3 2026 Earnings | XGN Stock NewsEXAGEN DIAGNOSTICS reported Q3 2026 earnings of -$0.25 per share, missing estimates by $0.07, and revenue of $18.42 million, missing estimates by $106,288. Insiders traded 3 times in 6 months, with 2 sales and 1 purchase, while 29 institutional investors added shares and 30 reduced positions.GlobeNewswireExagen Inc. Reports Third Quarter 2026 Financial ResultsExagen reported third-quarter 2026 revenue of $18.4 million, up 7% year-over-year, with a net loss of $6.3 million and adjusted EBITDA loss of $1.9 million. The company reiterated full-year 2026 revenue guidance of $72 million to $75 million and plans to launch its myositis offering early in 2027.